SAM CHUN DANG PHARM CO. LTD
000250 | KO
Overview
Corporate Details
- ISIN(s):
- KR7000250001
- LEI:
- Country:
- South Korea
- Address:
- 경기도 화성시 향남읍 제약공단2길 71, 화성시
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-19 00:00 |
Share Issue/Capital Change
[기재정정]주요사항보고서(교환사채권발행결정)
|
Korean | 30.5 KB | ||
| 2025-09-19 00:00 |
Transaction in Own Shares
[기재정정]주요사항보고서(자기주식처분결정)
|
Korean | 40.4 KB | ||
| 2025-09-19 00:00 |
Transaction in Own Shares
자기주식처분결과보고서
|
Korean | 22.0 KB | ||
| 2025-09-19 00:00 |
Share Issue/Capital Change
증권발행결과(자율공시)
|
Korean | 7.4 KB | ||
| 2025-08-27 00:00 |
Capital/Financing Update
주요사항보고서(교환사채권발행결정)
|
Korean | 25.0 KB | ||
| 2025-08-27 00:00 |
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
|
Korean | 32.5 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 2.2 MB | ||
| 2025-07-30 00:00 |
AGM Information
임시주주총회결과
|
Korean | 9.2 KB | ||
| 2025-07-24 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 100.9 KB | ||
| 2025-07-24 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 25.2 KB | ||
| 2025-07-24 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-07-07 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 61.1 KB | ||
| 2025-06-30 00:00 |
Regulatory Filings
[기재정정]단일판매ㆍ공급계약체결(자율공시)
|
Korean | 19.9 KB | ||
| 2025-06-24 00:00 |
Director's Dealing
임원ㆍ주요주주특정증권등거래계획보고서
|
Korean | 41.3 KB | ||
| 2025-06-24 00:00 |
Director's Dealing
임원ㆍ주요주주특정증권등거래계획보고서
|
Korean | 41.2 KB |
Automate Your Workflow. Get a real-time feed of all SAM CHUN DANG PHARM CO. LTD filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for SAM CHUN DANG PHARM CO. LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SAM CHUN DANG PHARM CO. LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Canada
OBI
Developing less toxic, tumor-agnostic kinase inhibitors for precision cancer therapy.
United States of America
OKUR
United States of America
OKUR
Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.
Japan
4528
Japan
4528
Developing precision-guided therapeutics using small antibodies for complex diseases.
France
ALONX
France
ALONX
A biopharma and diagnostics firm offering novel therapies and full-service clinical lab testing.
United States of America
OPK
United States of America
OPK
Biopharma that discontinued its wet AMD therapy after its lead drug failed Phase 3 trials.
United States of America
OPT
United States of America
OPT
Develops microbiome-modulating ingredients and supplements to manage chronic lifestyle diseases.
United Kingdom
OPTI
United Kingdom
OPTI
Develops and manufactures ophthalmic solutions for dry eye, infections, and inflammation.
South Korea
131030
South Korea
131030
Developing gene therapies for inherited retinal diseases and other blinding conditions.
United States of America
IRD
United States of America
IRD
Develops oral drug delivery systems to turn injectable drugs, like insulin, into oral therapies.
Israel
ORMP
Israel
ORMP